Corrigendum: Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study

Autor: Mark M. Awad, Yvan Le Bruchec, Brian Lu, Jason Ye, Julie Ann Miller, Patrick H. Lizotte, Megan E. Cavanaugh, Amanda J. Rode, Calin Dan Dumitru, Alexander Spira

Publikováno v: Frontiers in Oncology, Vol 12 (2022)

Externí odkaz: https://doaj.org/article/3963600921ff4ed4ab2f25dbc17d9408

Supplementary Data from CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

Autor: Kwok-Kin Wong, Nathanael S. Gray, David A. Barbie, Geoffrey I. Shapiro, Haribabu Arthanari, Norman E. Sharpless, W. Nicholas Haining, Jerome Ritz, Gordon J. Freeman, Sangeetha Palakurthi, Raphael Bueno, Genevieve M. Boland, Viswanath Gunda, Sareh Parangi, Jochen H. Lorch, William G. Richards, Jay C. Strum, Patrick J. Roberts, Eric Haines, Amanda J. Rode, Megan E. Cavanaugh, Ting Chen, Peng Gao, Hua Zhang, Yanxi Zhang, Annan Yang, Lauren E. Bufe, Max M. Quinn, Ashley A. Merlino, Patrick H. Lizotte, John E. Bisi, Jessica A. Sorrentino, Grit S. Herter-Sprie, Chensheng W. Zhou, Michaela Bowden, Cloud P. Paweletz, Elena Ivanova, Amir R. Aref, Hongye Liu, Wei Huang, Sandeep Chhabra, Kathleen Yates, Ruben Dries, Shuai Li, Russell W. Jenkins, Eric S. Wang, Jiehui Deng

Figure S1. Characterization of cells and CDK4/6 inhibitors; Figure S2. CDK6 phosphorylates serine residues of the regulatory domain of NFAT4 (NFATc3); Figure S3. Analysis of lung tumor immune infiltrates after CDK4/6 inhibition from KrasG12D (Kras),

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22a01c7e72b06ed917fff29065c873f6
https://doi.org/10.1158/2159-8290.22531849.v1

Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival

Autor: Eirini Pectasides, Sarah Derks, Charles S. Fuchs, Megan E. Cavanaugh, Peter C. Enzinger, Anuj K. Patel, Amanda J. Rode, Douglas A. Rubinson, Adam J. Bass, Bridget Fitzpatrick, Lauren K. Brais, Nadine Jackson McCleary, Mariano Severgnini, Patrick H. Lizotte, Fahire G Akarca, Jeffrey W. Clark, Leonie K. de Klerk, Melissa G Jean, Matthew Nazzaro, Jeremy Augustin, Mohamed Uduman, James M. Cleary, Hui Zheng, Nihal Raman

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 9 (2021)
Journal for Immunotherapy of Cancer, 9(9):e002472. BioMed Central
de Klerk, L K, Patel, A K, Derks, S, Pectasides, E, Augustin, J, Uduman, M, Raman, N, Akarca, F G, McCleary, N J, Cleary, J M, Rubinson, D A, Clark, J W, Fitzpatrick, B, Brais, L K, Cavanaugh, M E, Rode, A J, Jean, M G, Lizotte, P H, Nazzaro, M J, Severgnini, M, Zheng, H, Fuchs, C S, Enzinger, P C & Bass, A J 2021, ' Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival ', Journal for Immunotherapy of Cancer, vol. 9, no. 9, e002472 . https://doi.org/10.1136/jitc-2021-002472, https://doi.org/10.1136/jitc-2021-002472
Journal for Immunotherapy of Cancer

BackgroundImmune checkpoint inhibitors have revolutionized cancer treatment, but the benefits in refractory patients with esophageal cancer have been modest. Predictors of response as well as new targets for novel therapeutic combinations are needed.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c810cbc651fe7a89668ba3764f6711a
https://jitc.bmj.com/content/9/9/e002472.full

Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck

Autor: Jochen H. Lorch, Robert E. Jones, Kwok-Kin Wong, Peter S. Hammerman, Hongye Liu, Jonathan D. Schoenfeld, Elena Ivanova, Amanda J. Rode, Glenn J. Hanna, Mark A. Bittinger, Patrick H. Lizotte, Nicole G. Chau, Ravindra Uppaluri, Megan E. Cavanaugh, Robert I. Haddad, A. Bacay

Publikováno v: Oral oncology. 67

Objectives Immune checkpoint inhibitors have demonstrated clinical benefit in recurrent, metastatic (R/M) squamous cell carcinoma of the head and neck (SSCHN), but lacking are biomarkers that predict response. We sought to define an inflamed tumor im

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb7d84b93f3c5d6ca6293ef58e541161
https://pubmed.ncbi.nlm.nih.gov/28351582